The Weiss Lab, which features a multi-disciplinary team at Johns Hopkins as well as at Cedars Sinai Medical Center in Los Angeles, is dedicated to identifying the most important clinical, genetic, structural, contractile and metabolic causes of sudden cardiac death as well as the means to reverse the underlying pathology and lower risk. Current projects include research into energy metabolism in human heart failure and creatine kinase metabolism in animal models of heart failure. Robert G. Weiss, MD, is professor of medicine, Radiology and Radiological Science, at the Johns Hopkins University.

The mission and interest of the neuroengineering and Biomedical Instrumentation Lab is to develop novel instrumentation and technologies to study the brain at several levels--from single cell to the whole brain--with the goal of translating the work into practical research and clinical applications. Our personnel include diverse, independent-minded and entrepreneurial students, post docs, and research faculty who base their research on modern microfabrication, stem cell biology, electrophysiology, signal processing, image processing, and integrated circuit design technologies.

The Laboratory for Integrated NanoDiagnostics (LIND) is developing innovative technologies for accurate, fast, compact, portable, manufacturable, low-cost diagnostics for a wide variety of applications. Our current focus is a large-scale collaboration with imec, a leading microelectronics company in Leuven, Belgium, where our silicon is designed and manufactured. With major funding from miDiagnostics we are inventing solutions that are opening new avenues.

Our mission is to reveal the molecular logic of our intelligence in health and disease. We use advanced molecular biological tools and state-of-the-art neuroscience to test the role of synaptic and neuronal molecules in the dynamics of the living brain.

Artificial neural networks have been heavily inspired by the brain’s architecture, guiding our journey to discovering the keys to intelligence. We now find ourselves at a pivotal moment: today's AI systems surpass biological circuits in certain tasks, yet we still lack a fundamental understanding of the mechanisms behind the brain’s superior cognitive flexibility and efficiency. At Ingie Hong’s Quantitative Intelligence Lab, we are dedicated to unraveling the principles that enable the mammalian cortex to achieve remarkable feats of intelligence, including rapid learning, generalization, and inference across vast stores of memory.

A single neuron’s response depends on its synaptic connections and intrinsic properties, which are dictated by the expression of neuronal genes. However, the role of these molecules in brain computations remains largely uncharted territory. Focusing on the mouse visual cortex as a starting point for broader generalization, and using large-scale electrophysiology, advanced microscopy, and machine learning, we have begun to uncover the impact of key synaptic genes on cortical processing and their role in the brain’s “working algorithm” (Hong et al., Nature, 2024). Our molecular tools, including gene therapy vectors and antisense oligonucleotides, show promise as effective therapeutic candidates.

Our research will advance the nascent field of 'neurocomputational therapeutics'—innovative genetic and pharmacological tools that address biases in neural activity. These tools will not only facilitate the development of novel mechanism-based treatments for brain disorders but also inspire the next generation of intelligent artificial neural networks.

The Frueh Laboratory uses nuclear magnetic resonance (NMR) to study how protein dynamics can be modulated and how active enzymatic systems can be conformed. Non-ribosomal peptide synthetases (NRPS) are large enzymatic systems that biosynthesize secondary metabolites, many of which are used by pharmaceutical scientists to produce drugs such as antibiotics or anticancer agents. Dr. Frueh's laboratory uses NMR to study inter- and intra-domain modifications that occur during the catalytic steps of NRPS. Dr. Frueh and his team are constantly developing new NMR techniques to study these complicated enzymatic systems.

Researchers in the Center for Cell Dynamics study spatially and temporally regulated molecular events in living cells, tissues and organisms. The team develops and applies innovative biosensors and imaging techniques to monitor dozens of critical signaling pathways in real time. The new tools help them investigate the fundamental cellular behaviors that underlie embryonic development, wound healing, cancer progression, and functions of the immune and nervous systems.

Researchers in the Ami Shah Lab study scleroderma and Raynaud’s phenomenon. We examine the relationship between cancer and scleroderma, with a focus on how and if cancer causes scleroderma to develop in some patients. We are currently conducting clinical research to study ways to detect cardiopulmonary complications in patients with scleroderma, biological and imaging markers of Raynaud’s phenomenon, and drugs that improve aspects of scleroderma.

The clinical development of novel immune and stem cell therapies calls for suitable methods that can follow the fate of cells non-invasively in humans at high resolution. The Bulte Lab has pioneered methods to label cells magnetically (using tiny superparamagnetic iron oxide nanoparticles) in order to make them visible by MR imaging. While the lab is doing basic bench-type research, there is a strong interaction with the clinical interventional radiology and oncology groups in order to bring the methodologies into the clinic.

Research in the Gregory Kirk Lab examines the natural history of viral infections — particularly HIV and hepatitis viruses — in the U.S. and globally. As part of the ALIVE (AIDS Linked to the Intravenous Experience) study, our research looks at a range of pathogenetic, clinical behavioral issues, with a special focus on non-AIDS-related outcomes of HIV, including cancer and liver and lung diseases. We use imaging and clinical, genetic, epigenetic and proteomic methods to identify and learn more about people at greatest risk for clinically relevant outcomes from HIV, hepatitis B and hepatitis C infections. Our long-term goal is to translate our findings into targeted interventions that help reduce the disease burden of these infections.

The Johns Hopkins Laboratory of Computational Intensive Care Medicine (LCICM) has been established to gain knowledge on the mechanisms of critical illness and injury, with the aim of identifying novel methods to treat patients admitted to the intensive care unit (ICU). Members of the lab apply mathematical and statistical models, artificial intelligence, and domain expertise to unravel patterns in data from sources such as electronic health records, high-frequency physiological recordings, and medical imaging. These patterns are resolved into health signatures that can be leveraged for classification and prediction. The overarching goal is to enhance the precision, efficacy, and outcomes of care delivered to critically ill patients.